- PackSize
- 50ug/100ug
- Target
- Complement receptor C3 subunit beta
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Humanized
- Isotype
- IgG4-nd
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- Complement receptor C3 subunit beta, Cell surface adhesion glycoproteins LFA-1/CR3/p150, 95 subunit beta, Integrin beta-2, MFI7, CD18, ITGB2, CD11A, Leukocyte function-associated molecule 1 alpha chain, Leukocyte adhesion glycoprotein LFA-1 alpha chain, LFA-1A, CD11 antigen-like family member A, CD11a, ITGAL, Integrin alpha-L, CR-3 alpha chain, Cell surface glycoprotein MAC-1 subunit alpha, Leukocyte adhesion receptor MO1, ITGAM, CD11b, CD11 antigen-like family member B, Integrin alpha-M, CR3A, CD11B, Neutrophil adherence receptor
- Species
- --
- Gene ID-1
- P05107, P20701, P11215
- Uniprot
- --
- Background
- Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.<br>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --